Colorectal Cancer (CRC) Clinical Trials
0 recruiting
Showing 1–10 of 10 trials
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Non-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Advanced Solid Malignancies+1 more
Bristol-Myers Squibb252 enrolled8 locationsNCT07223047
Recruiting
Phase 2
Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Non-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Solid Tumor+1 more
Guangzhou JOYO Pharma Co., Ltd210 enrolled1 locationNCT06895031
Recruiting
Phase 1
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Pancreatic CancerNon-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)+7 more
Revolution Medicines, Inc.574 enrolled5 locationsNCT07349537
Recruiting
Phase 1Phase 2
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Non-small Cell Lung Cancer (NSCLC)Advanced Solid TumorsNSCLC+3 more
Revolution Medicines, Inc.370 enrolled1 locationNCT07397338
Recruiting
Not Applicable
Reduce Sedentary Behavior During Cancer Treatment - the RedSedCan Study
Breast CancerProstate CancerNeoadjuvant Therapy+2 more
Mälardalen University172 enrolled2 locationsNCT06719206
Recruiting
Phase 1Phase 2
Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors
Squamous Cell Carcinoma of Head and NeckSolid TumorColorectal Cancer (CRC)
One-carbon Therapeutics AB43 enrolled4 locationsNCT07151040
Recruiting
Phase 1Phase 2
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Non-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Advanced Solid Tumors+1 more
Revolution Medicines, Inc.754 enrolled16 locationsNCT05379985
Recruiting
Phase 1Phase 2
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
Pancreatic Ductal Adenocarcinoma (PDAC)Colorectal Cancer (CRC)Clear Cell Renal Cell Cancer (ccRCC)+4 more
ITM Oncologics GmbH270 enrolled10 locationsNCT05706129
Recruiting
Phase 1
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Non-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Advanced Solid Tumors+1 more
Revolution Medicines, Inc.604 enrolled17 locationsNCT06040541
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
Advanced Solid TumorMetastatic Solid TumorSoft Tissue Sarcoma (STS)+3 more
GI Innovation, Inc.358 enrolled11 locationsNCT05824975